The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer.

Szczegóły
Abstrakt

Tytuł:: The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer.
Autorzy:: Bilusic M; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, 13n240b, Bethesda, MD 20892, USA.
Einstein DJ; Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Karzai FH; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, 13n240b, Bethesda, MD 20892, USA.
Dahut WL; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, 13n240b, Bethesda, MD 20892, USA.
Gulley JL; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, 13n240b, Bethesda, MD 20892, USA.
Aragon-Ching JB; GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA, USA.
Madan RA; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, 13n240b, Bethesda, MD 20892, USA. Electronic address: .
Źródło:: The Urologic clinics of North America [Urol Clin North Am] 2020 Nov; Vol. 47 (4), pp. 457-467.
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Original Publication: Philadelphia, Saunders.
MeSH Terms:: Androgen Antagonists/*therapeutic use
Immunotherapy/*methods
Neoplasm Recurrence, Local/*therapy
Prostatic Neoplasms/*pathology
Aged ; Combined Modality Therapy ; Disease-Free Survival ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local/diagnostic imaging ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/pathology ; Patient Selection ; Prognosis ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/mortality ; Prostatic Neoplasms/therapy ; Risk Assessment ; Role ; Survival Analysis ; Tomography, X-Ray Computed/methods ; Treatment Outcome
References:: Clin Cancer Res. 2011 Jul 1;17(13):4558-67. (PMID: 21558406)
CA Cancer J Clin. 2020 Jan;70(1):7-30. (PMID: 31912902)
Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9287-92. (PMID: 10430935)
Oncologist. 2010;15(9):969-75. (PMID: 20798195)
Lancet. 2016 Mar 19;387(10024):1163-77. (PMID: 26719232)
J Clin Oncol. 2005 May 1;23(13):2918-25. (PMID: 15860850)
JAMA. 2005 Jul 27;294(4):433-9. (PMID: 16046649)
Nature. 2018 Jul;559(7714):363-369. (PMID: 29950727)
J Urol. 2007 Feb;177(2):540-5. (PMID: 17222629)
Oncoimmunology. 2016 Jul 01;5(8):e1197459. (PMID: 27622067)
Urology. 1999 Nov;54(5):884-90. (PMID: 10565752)
PLoS One. 2020 May 26;15(5):e0233260. (PMID: 32453797)
Eur Urol. 2019 Oct;76(4):517-523. (PMID: 30987843)
J Clin Oncol. 2020 Feb 10;38(5):395-405. (PMID: 31774688)
Br J Urol. 1997 Feb;79(2):235-46. (PMID: 9052476)
Radiology. 2017 Dec;285(3):728-743. (PMID: 29155624)
J Nucl Med. 2018 Nov;59(11):1665-1671. (PMID: 29602821)
J Urol. 2007 Oct;178(4 Pt 1):1515-20. (PMID: 17707059)
Biomed Res Int. 2015;2015:794968. (PMID: 26161414)
J Clin Oncol. 2009 Sep 1;27(25):4047-54. (PMID: 19636017)
Pract Radiat Oncol. 2011;1(4):235-242. (PMID: 22025934)
Clin Cancer Res. 2014 Jul 15;20(14):3692-704. (PMID: 24850844)
J Urol. 2004 Sep;172(3):910-4. (PMID: 15310996)
J Clin Oncol. 2010 Mar 1;28(7):1099-105. (PMID: 20100959)
Cancer Med. 2019 Jul;8(8):4023-4031. (PMID: 31165589)
J Clin Oncol. 2007 May 1;25(13):1765-71. (PMID: 17470867)
J Nucl Med. 2018 Jan;59(1):82-88. (PMID: 28646014)
Clin Cancer Res. 2017 Nov 15;23(22):6812-6822. (PMID: 28893901)
N Engl J Med. 2017 Jul 27;377(4):338-351. (PMID: 28578639)
Clin Cancer Res. 2016 Apr 15;22(8):1969-77. (PMID: 26573597)
J Natl Cancer Inst. 2003 Sep 17;95(18):1376-83. (PMID: 13130113)
J Clin Oncol. 2019 May 1;37(13):1051-1061. (PMID: 30817251)
Lancet Oncol. 2016 Jun;17(6):727-737. (PMID: 27155740)
Eur Urol. 2020 Mar;77(3):333-341. (PMID: 31640893)
Clin Cancer Res. 2017 May 15;23(10):2451-2459. (PMID: 27836866)
J Clin Oncol. 2007 Apr 20;25(12):1596-605. (PMID: 17404365)
Science. 2018 Oct 12;362(6411):. (PMID: 30309915)
Cancer. 2012 Mar 15;118(6):1533-42. (PMID: 21960118)
Trends Cancer. 2016 Dec;2(12):713-722. (PMID: 28138568)
Cancer. 2008 Jan 1;112(1):55-60. (PMID: 17968996)
Eur J Cancer. 2015 May;51(7):817-24. (PMID: 25794605)
J Clin Oncol. 2017 Jan;35(1):40-47. (PMID: 28034081)
J Clin Oncol. 2017 Sep 20;35(27):3097-3104. (PMID: 28796587)
Cell. 2019 Nov 14;179(5):1177-1190.e13. (PMID: 31730856)
JAMA. 1999 May 5;281(17):1591-7. (PMID: 10235151)
Prostate Cancer Prostatic Dis. 2004;7(3):217-22. (PMID: 15278095)
Cancer Cell. 2005 Nov;8(5):393-406. (PMID: 16286247)
N Engl J Med. 2015 Aug 20;373(8):737-46. (PMID: 26244877)
Lancet Oncol. 2014 Jun;15(7):700-12. (PMID: 24831977)
J Clin Oncol. 2008 Mar 1;26(7):1148-59. (PMID: 18309951)
J Clin Oncol. 2010 Jun 20;28(18):3090-5. (PMID: 20458026)
Cancer. 2010 Apr 15;116(8):1887-92. (PMID: 20162710)
Target Oncol. 2016 Jun;11(3):345-51. (PMID: 26566945)
N Engl J Med. 2010 Jul 29;363(5):411-22. (PMID: 20818862)
N Engl J Med. 2012 Sep 6;367(10):895-903. (PMID: 22931259)
Oncotarget. 2018 May 22;9(39):25586-25596. (PMID: 29876010)
Oncoimmunology. 2016 Mar 28;5(6):e1165377. (PMID: 27471641)
J Clin Oncol. 2019 Dec 20;37(36):3507-3517. (PMID: 31644357)
J Urol. 2005 Mar;173(3):797-802. (PMID: 15711272)
Cancer Immunol Res. 2015 Aug;3(8):946-55. (PMID: 26041735)
Eur Urol. 2015 Sep;68(3):365-71. (PMID: 25533418)
Grant Information:: ZIA BC010666 United States ImNIH Intramural NIH HHS
Contributed Indexing:: Keywords: Biochemically recurrent; Immunotherapy-based treatment; Prostate cancer; Systemic therapy
Substance Nomenclature:: 0 (Androgen Antagonists)
EC 3.4.21.77 (Prostate-Specific Antigen)
Entry Date(s):: Date Created: 20201003 Date Completed: 20201013 Latest Revision: 20240402
Update Code:: 20240402
PubMed Central ID:: PMC8177734
DOI:: 10.1016/j.ucl.2020.07.004
PMID:: 33008496
: Czasopismo naukowe

Biochemically recurrent prostate cancer represents a stage of prostate cancer where conventional (continued on next page) computed tomography and technetium Tc 99m bone scan imaging are unable to detect disease after curative intervention despite rising prostate-specific antigen. There is no clear standard of care and no systemic therapy has been shown to improve survival. Immunotherapy-based treatments potentially are attractive options relative to androgen deprivation therapy due to the generally more favorable side-effect profile. Biochemically recurrent prostate cancer patients have a low tumor burden and likely lymph node-based disease, which may make them more likely to respond to immunotherapy.
(Published by Elsevier Inc.)

Informacja